Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

CCCC

C4 Therapeutics Inc

May 03 • 12:29PM ET

6.59

Dollar change +0.16
Percentage change 2.54	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF LABU SCHA DFAT DFAS DFAC IWC AVSC ITOT

Index	-	P/E	-	EPS (ttm)	-2.67	Insider Own	15.88%	Shs Outstand	60.47M	Perf Week	6.86%
Market Cap	453.69M	Forward P/E	-	EPS next Y	-1.88	Insider Trans	0.00%	Shs Float	57.88M	Perf Month	-14.59%
Income	-132.49M	PEG	-	EPS next Q	-0.36	Inst Own	71.55%	Short Float	16.52%	Perf Quarter	22.78%
Sales	20.76M	P/S	21.85	EPS this Y	30.76%	Inst Trans	-1.55%	Short Ratio	4.17	Perf Half Y	399.50%
Book/sh	4.07	P/B	1.62	EPS next Y	-1.95%	ROA	-32.82%	Short Interest	9.56M	Perf Year	109.98%
Cash/sh	3.69	P/C	1.79	EPS next 5Y	22.30%	ROE	-49.50%	52W Range	1.06 - 11.88	Perf YTD	16.70%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-36.05%	ROI	-42.48%	52W High	-44.50%	Beta	3.23
Dividend TTM	-	Quick Ratio	6.34	Sales past 5Y	7.65%	Gross Margin	62.72%	52W Low	522.02%	ATR (14)	0.44
Dividend Ex-Date	-	Current Ratio	6.34	EPS Y/Y TTM	-1.78%	Oper. Margin	-669.84%	RSI (14)	40.26	Volatility	4.68% 5.57%
Employees	145	Debt/Eq	0.29	Sales Y/Y TTM	-33.25%	Profit Margin	-638.34%	Recom	1.67	Target Price	17.22
Option/Short	Yes / Yes	LT Debt/Eq	0.27	EPS Q/Q	10.64%	Payout	-	Rel Volume	0.31	Prev Close	6.43
Sales Surprise	1.92%	EPS Surprise	1.00%	Sales Q/Q	14.26%	Earnings	Feb 22 BMO	Avg Volume	2.29M	Price	6.59
SMA20	-4.78%	SMA50	-21.36%	SMA200	40.18%	Trades		Volume	346,120	Change	2.54%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-24	Upgrade	JP Morgan	Underweight → Neutral	$6
Dec-13-23	Upgrade	Stifel	Hold → Buy	$2 → $12
Feb-24-23	Upgrade	Credit Suisse	Underperform → Neutral	$12 → $10
Feb-24-23	Downgrade	JP Morgan	Neutral → Underweight	$15 → $5
Nov-04-22	Downgrade	JP Morgan	Overweight → Neutral	$22 → $15
Oct-11-22	Initiated	Morgan Stanley	Underweight	$6
Apr-28-22	Initiated	Credit Suisse	Underperform	$10
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral	$46 → $15
Mar-10-22	Initiated	JP Morgan	Overweight	$43
Feb-11-22	Resumed	BMO Capital Markets	Outperform	$57
Feb-10-22	Initiated	Wells Fargo	Equal Weight	$25
Nov-23-21	Initiated	BofA Securities	Buy	$54
Oct-14-21	Initiated	SVB Leerink	Mkt Perform	$20
Sep-30-21	Initiated	Stifel	Hold	$45
Jun-04-21	Initiated	H.C. Wainwright	Buy	$63
Mar-31-21	Initiated	BMO Capital Markets	Outperform	$55
Oct-28-20	Initiated	UBS	Buy	$44
Oct-27-20	Initiated	Jefferies	Buy	$34
Oct-27-20	Initiated	BMO Capital Markets	Outperform	$33

Show Previous Ratings

Apr-29-24 04:01PM	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-09-24 07:00AM	C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum (GlobeNewswire)
Apr-08-24 08:00AM	C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-28-24 04:36AM	Here's Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC) (Insider Monkey)
Mar-05-24 04:30PM	C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC Degraders at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
07:00AM	Loading…
Mar-04-24 07:00AM	C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins (GlobeNewswire)
Feb-22-24 08:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +21.38%
07:36AM	C4 Therapeutics Inc (CCCC) Reports Full Year 2023 Financial Results and Business Updates (GuruFocus.com)
07:00AM	C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-15-24 10:19AM	C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store? (Zacks) +8.07%
10:00AM	C4 Therapeutics, Inc. (CCCC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Jan-11-24 11:44AM	C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn (Zacks) -5.97%
Jan-09-24 06:20PM	C4 Therapeutics, Inc. (CCCC)'s Technical Outlook is Bright After Key Golden Cross (Zacks) +6.90%
04:01PM	C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines (GlobeNewswire)
Jan-04-24 04:01PM	C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals (GlobeNewswire) +9.69%
07:00AM	Loading…
07:00AM	C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-03-24 11:10AM	C4 Therapeutics (CCCC) Gains 310% in 3 Months: Here's Why (Zacks) -11.35%
Jan-01-24 09:55AM	Wall Street Analysts See a 197.7% Upside in C4 Therapeutics, Inc. (CCCC): Can the Stock Really Move This High? (Zacks)
Dec-27-23 07:35PM	11 Hot Healthcare Stocks To Buy Now (Insider Monkey)
Dec-15-23 09:55AM	Wall Street Analysts Think C4 Therapeutics, Inc. (CCCC) Could Surge 222.95%: Read This Before Placing a Bet (Zacks)
Dec-13-23 12:39PM	C4 Therapeutics (CCCC) Soars on Oncology Deal With Merck (Zacks) +135.47%
Dec-12-23 04:01PM	C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma (GlobeNewswire) +98.31%
10:13AM	Why Is C4 Therapeutics (CCCC) Stock Up 72% Today? (InvestorPlace)
07:00AM	C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs) (GlobeNewswire)
Nov-28-23 07:00AM	C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
Nov-20-23 07:00AM	C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment (GlobeNewswire) -6.63%
Nov-13-23 09:55AM	Here's Why C4 Therapeutics, Inc. (CCCC) Looks Ripe for Bottom Fishing (Zacks)
Nov-01-23 11:03AM	C4 Therapeutics discontinues cancer program, waits for Betta payment (FierceBiotech.com) -11.41%
09:40AM	C4 Therapeutics Inc (CCCC) Reports Q3 2023 Financial Results and Business Highlights (GuruFocus.com)
07:00AM	C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
07:00AM	Loading…
Oct-11-23 07:00AM	C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC Degrader in Development for Multiple Myeloma and Non-Hodgkin's Lymphoma (GlobeNewswire)
Sep-05-23 04:01PM	C4 Therapeutics Announces Chief Financial Officer Succession (GlobeNewswire) -7.29%
Aug-28-23 06:30PM	12 Best High Risk Penny Stocks to Buy Now (Insider Monkey)
Aug-08-23 08:40AM	C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-04-23 06:58AM	With 64% institutional ownership, C4 Therapeutics, Inc. (NASDAQ:CCCC) is a favorite amongst the big guns (Simply Wall St.)
Jul-17-23 07:00AM	C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-05-23 07:00AM	C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer (GlobeNewswire) +17.31%
Jun-20-23 07:00AM	C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer (GlobeNewswire) -7.72%
May-30-23 07:00AM	C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC Degrader of EGFR L858R for NSCLC (GlobeNewswire) +8.77%
May-14-23 08:06AM	Broker Revenue Forecasts For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher (Simply Wall St.)
May-04-23 08:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-19-23 07:00AM	C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days (GlobeNewswire)
Apr-11-23 09:35AM	Down -29.73% in 4 Weeks, Here's Why You Should You Buy the Dip in C4 Therapeutics, Inc. (CCCC) (Zacks)
Mar-23-23 07:39AM	Insiders who bought this year lost US$59k as C4 Therapeutics, Inc. (NASDAQ:CCCC) sheds US$27m in value (Simply Wall St.)
Feb-24-23 05:38AM	C4 Therapeutics Full Year 2022 Earnings: Misses Expectations (Simply Wall St.) -11.46%
Feb-23-23 08:35AM	C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-08-23 07:00AM	C4 Therapeutics to Present at Two Virtual February 2023 Conferences (GlobeNewswire) -5.86%
Jan-30-23 07:00AM	C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC Degrader, in BRAF V600 Mutant Solid Tumors (GlobeNewswire)
Jan-09-23 07:00AM	C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines (GlobeNewswire) +6.40%
Jan-05-23 06:15PM	C4 Therapeutics, Inc. (CCCC) Dips More Than Broader Markets: What You Should Know (Zacks)
Jan-04-23 09:40AM	Are Medical Stocks Lagging AMN Healthcare Services (AMN) This Year? (Zacks)
Jan-03-23 07:00AM	C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +8.14%
Nov-13-22 07:13AM	The past year for C4 Therapeutics (NASDAQ:CCCC) investors has not been profitable (Simply Wall St.)
Nov-08-22 09:55AM	Wall Street Analysts Think C4 Therapeutics, Inc. (CCCC) Could Surge 227%: Read This Before Placing a Bet (Zacks)
Nov-03-22 08:25AM	C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-02-22 10:01AM	C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -5.27%
Oct-03-22 09:02AM	One C4 Therapeutics, Inc. (NASDAQ:CCCC) insider upped their stake in the previous year (Simply Wall St.)
Sep-29-22 07:00AM	C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC Degrader, in BRAF-V600 Mutant Solid Cancers (GlobeNewswire) -5.01%
Sep-26-22 07:00AM	C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022 (GlobeNewswire)
Sep-06-22 08:22AM	With 63% ownership of the shares, C4 Therapeutics, Inc. (NASDAQ:CCCC) is heavily dominated by institutional owners (Simply Wall St.)
Aug-10-22 06:05AM	Growth Investors: Industry Analysts Just Upgraded Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Revenue Forecasts By 16% (Simply Wall St.)
Aug-07-22 08:21AM	Analysts Are Upgrading C4 Therapeutics, Inc. (NASDAQ:CCCC) After Its Latest Results (Simply Wall St.)
Aug-04-22 09:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +6.95%
08:00AM	C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-02-22 08:00AM	C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors (GlobeNewswire) +6.01%
May-16-22 08:00AM	C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors (GlobeNewswire) -6.15%
May-05-22 09:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-08-22 02:15PM	C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma Trial (Benzinga) -50.57%
01:00PM	C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader (GlobeNewswire)
10:05AM	Investors one-year losses grow to 32% as the stock sheds US$66m this past week (Simply Wall St.)
Mar-17-22 11:44AM	J.P. Morgan Says Theres Room for Over 80% Gains in These 2 Stocks (TipRanks) +5.92%
Mar-16-22 04:05PM	C4 Therapeutics Appoints Utpal Koppikar to Board of Directors (GlobeNewswire) +5.30%
Mar-09-22 08:00AM	C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma (GlobeNewswire) +15.29%
Mar-08-22 04:30PM	C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022 (GlobeNewswire)
Feb-24-22 07:00AM	C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights (GlobeNewswire) +13.96%
Feb-07-22 04:45AM	What Is The Ownership Structure Like For C4 Therapeutics, Inc. (NASDAQ:CCCC)? (Simply Wall St.)
Jan-12-22 11:09AM	Is C4 Therapeutics, Inc. (CCCC) A Good Stock To Buy? (Insider Monkey)
Jan-10-22 07:00AM	C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio (GlobeNewswire) +8.52%
Jan-03-22 07:00AM	C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-29-21 12:00PM	What Makes C4 Therapeutics, Inc. (CCCC) a New Buy Stock (Zacks)
Dec-17-21 08:00AM	C4 Therapeutics Added to NASDAQ Biotechnology Index (GlobeNewswire)
Dec-01-21 07:28AM	C4 Therapeutics (CCCC) Sees Hammer Chart Pattern: Time to Buy? (Zacks) -7.35%
Nov-22-21 12:00PM	C4 Therapeutics, Inc. (CCCC) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Nov-10-21 04:01PM	C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results (GlobeNewswire)
08:34AM	Why C4 Therapeutics (CCCC) Might Surprise This Earnings Season (Zacks)
Oct-26-21 10:41AM	Hedge Funds Are Piling Into C4 Therapeutics, Inc. (CCCC) (Insider Monkey)
Oct-09-21 09:14AM	C4 Therapeutics (NASDAQ:CCCC) pulls back 8.2% this week, but still delivers shareholders notable 85% return over 1 year (Simply Wall St.)
Sep-17-21 10:27AM	Director Of C4 Therapeutics Sold $3.98 Million In Stock (Benzinga)
Aug-11-21 04:02PM	C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results (GlobeNewswire)
04:01PM	C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma (GlobeNewswire)
Aug-10-21 01:31AM	Is C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Shareholder Ownership Skewed Towards Insiders? (Simply Wall St.)
Jul-21-21 04:24AM	Is C4 Therapeutics, Inc. (CCCC) A Good Stock To Buy Now? (Insider Monkey)
Jul-19-21 01:44PM	C4 Therapeutics Stock Enters Leadership Territory (Investor's Business Daily)
Jun-21-21 04:01PM	C4 Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)
08:00AM	C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the 16th Annual International Conference on Malignant Lymphoma (GlobeNewswire)

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.

Open in Screener

ASRT

Assertio Holdings Inc

May 03 • 12:29PM ET

1.01

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN PRFZ BSVO VTWO FDM IWC EES

Index	RUT	P/E	-	EPS (ttm)	-3.97	Insider Own	5.92%	Shs Outstand	94.67M	Perf Week	21.95%
Market Cap	96.07M	Forward P/E	202.00	EPS next Y	0.01	Insider Trans	-0.18%	Shs Float	89.49M	Perf Month	9.40%
Income	-331.94M	PEG	-	EPS next Q	-0.03	Inst Own	49.21%	Short Float	12.02%	Perf Quarter	28.66%
Sales	152.07M	P/S	0.63	EPS this Y	-121.82%	Inst Trans	11.52%	Short Ratio	11.14	Perf Half Y	-52.58%
Book/sh	1.46	P/B	0.69	EPS next Y	104.17%	ROA	-94.80%	Short Interest	10.76M	Perf Year	-83.00%
Cash/sh	0.77	P/C	1.31	EPS next 5Y	25.00%	ROE	-182.52%	52W Range	0.73 - 8.01	Perf YTD	-5.61%
Dividend Est.	-	P/FCF	1.96	EPS past 5Y	-	ROI	-186.50%	52W High	-87.39%	Beta	0.90
Dividend TTM	-	Quick Ratio	1.43	Sales past 5Y	-7.51%	Gross Margin	64.04%	52W Low	37.90%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	1.83	EPS Y/Y TTM	-272.27%	Oper. Margin	10.79%	RSI (14)	62.46	Volatility	8.87% 7.49%
Employees	53	Debt/Eq	0.30	Sales Y/Y TTM	-2.66%	Profit Margin	-218.28%	Recom	1.00	Target Price	3.00
Option/Short	Yes / Yes	LT Debt/Eq	0.29	EPS Q/Q	-145.92%	Payout	-	Rel Volume	0.45	Prev Close	1.01
Sales Surprise	-3.39%	EPS Surprise	-	Sales Q/Q	-34.49%	Earnings	May 06 AMC	Avg Volume	965.54K	Price	1.01
SMA20	17.03%	SMA50	10.17%	SMA200	-45.06%	Trades		Volume	210,239	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-07-22	Initiated	Lake Street	Buy	$7
Nov-30-18	Downgrade	Mizuho	Buy → Neutral

Apr-25-24 08:00AM	Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 (GlobeNewswire) -9.30%
Apr-03-24 08:00AM	Sig Kirk Joins Assertio Board of Directors (GlobeNewswire)
Apr-01-24 09:00AM	Assertio to Present at LD Micro Invitational Conference in New York City (GlobeNewswire)
Mar-12-24 11:11AM	Assertio Holdings Inc (ASRT) Reports Mixed Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com) +8.06%
08:31AM	Assertio Holdings, Inc. (NASDAQ:ASRT) Q4 2023 Earnings Call Transcript (Insider Monkey)
05:49AM	Loading…
05:49AM	Q4 2023 Assertio Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-11-24 04:26PM	Assertio: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Assertio Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-04-24 05:07PM	Assertio Holdings, Inc. Investors: Company Investigated by the Portnoy Law Firm (GlobeNewswire)
Feb-29-24 04:05PM	Assertio Holdings, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024 (GlobeNewswire)
Feb-28-24 10:15AM	Kessler Topaz Meltzer & Check, LLP Reminds Assertio Holdings, Inc. (ASRT) Investors of March 5, 2024 Lead Plaintiff Deadline and Urges Investors with Substantial Losses to Contact the Firm (PR Newswire)
Feb-26-24 07:57PM	Assertio Holdings, Inc. Investors: Company Investigated by the Portnoy Law Firm (GlobeNewswire)
Feb-23-24 11:30AM	ASSERTIO SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Assertio To Contact Him Directly To Discuss Their Options (GlobeNewswire)
05:45AM	Investors in Assertio Holdings, Inc. Should Contact Levi & Korsinsky Before March 5, 2024 to Discuss Your Rights - ASRT (PR Newswire)
Feb-22-24 12:35PM	Assertio Holdings, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky for More Information ASRT (GlobeNewswire)
12:39PM	Loading…
Feb-19-24 12:39PM	Analyst Slashes Assertio Holdings (ASRT) Price Target Amid CEO's Departure and Securities Fraud Suit Hagens Berman (GlobeNewswire)
Feb-16-24 12:41PM	Assertio Holdings (ASRT) Faces Lawsuit, Analyst Slashes Price Target Amid CEO's Departure Hagens Berman (GlobeNewswire)
11:28AM	Assertio Holdings Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
Feb-13-24 05:45AM	Shareholders of Assertio Holdings, Inc. Should Contact Levi & Korsinsky Before March 5, 2024 to Discuss Your Rights - ASRT (PR Newswire) -7.27%
Feb-12-24 10:30AM	Assertio Holdings (ASRT) Faces Lawsuit, Analyst Slashes Price Target Amid CEO's Departure Hagens Berman (GlobeNewswire) +7.90%
Feb-09-24 02:51PM	Analyst Slashes Assertio Holdings (ASRT) Price Target Amid CEO's Departure and Securities Fraud Suit Hagens Berman (GlobeNewswire)
Feb-05-24 03:56PM	Assertio Holdings, Inc. Investors: Company Investigated by the Portnoy Law Firm (GlobeNewswire)
10:24AM	Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why (Zacks)
10:08AM	Analyst Slashes Assertio Holdings (ASRT) Price Target Amid CEO's Departure and Securities Fraud Suit Hagens Berman (GlobeNewswire)
Feb-02-24 12:32PM	Assertio Holdings (ASRT) Faces Lawsuit, Analyst Slashes Price Target Amid CEO's Departure Hagens Berman (GlobeNewswire)
12:19PM	Assertio Holdings Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
Jan-29-24 12:30PM	Assertio Holdings (ASRT) Faces Lawsuit, Analyst Slashes Price Target Amid CEO's Departure Hagens Berman (GlobeNewswire) +5.96%
Jan-26-24 09:15AM	Analyst Slashes Assertio Holdings (ASRT) Price Target Amid CEO's Departure and Securities Fraud Suit Hagens Berman (GlobeNewswire)
Jan-24-24 06:54PM	Assertio Holdings, Inc. Investors: Company Investigated by the Portnoy Law Firm (GlobeNewswire)
10:15AM	ASSERTIO SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Assertio To Contact Him Directly To Discuss Their Options (GlobeNewswire)
03:42PM	Loading…
Jan-22-24 03:42PM	Assertio Holdings (ASRT) Faces Lawsuit as Analyst Slashes Price Target Amid CEO's Departure Hagens Berman (GlobeNewswire)
Jan-19-24 09:36AM	Assertio Holdings, Inc. (NASDAQ: ASRT) Securities Fraud: Contact Berger Montague To Discuss Your Rights (GlobeNewswire)
Jan-17-24 10:15AM	ASSERTIO SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Assertio To Contact Him Directly To Discuss Their Options (GlobeNewswire)
09:35AM	Assertio Holdings Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
Jan-15-24 03:29PM	Assertio Holdings (ASRT) Faces Lawsuit After CEO Sacked Hagens Berman (GlobeNewswire)
Jan-10-24 10:45AM	ASSERTIO SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Assertio To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Jan-08-24 12:14PM	Assertio Holdings Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire) -5.39%
Jan-05-24 06:56PM	Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +12.79%
Jan-04-24 09:46AM	Assertio (ASRT) Shares Fall as Dan Peisert Steps Down as CEO (Zacks) -10.91%
Jan-03-24 08:59AM	Assertio Holdings, Inc. Announces Leadership Transition (GlobeNewswire) -10.96%
Dec-25-23 02:06PM	Pre-Surge Penny Picks: 3 Stocks to Buy Before They Boom (InvestorPlace)
Nov-14-23 08:00AM	Assertio Holdings, Inc. Appoints Sravan Emany to Its Board of Directors (GlobeNewswire)
Nov-10-23 01:11PM	Assertio Holdings, Inc. (NASDAQ:ASRT) Q3 2023 Earnings Call Transcript (Insider Monkey) -7.44%
Nov-09-23 08:49AM	Q3 2023 Assertio Holdings Inc Earnings Call (Thomson Reuters StreetEvents) -43.19%
Nov-08-23 06:46PM	Assertio Holdings Inc (ASRT) Faces Headwinds in Q3 2023 Despite Revenue Growth (GuruFocus.com)
04:30PM	Assertio: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Assertio Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-02-23 12:06PM	Assertio Holdings, Inc. to Release Third Quarter 2023 Financial Results on November 8, 2023 (GlobeNewswire)
Oct-06-23 04:30PM	Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-22-23 08:38AM	Is the Options Market Predicting a Spike in Assertio (ASRT) Stock? (Zacks)
Sep-14-23 01:12PM	Insider Sell: SVP, General Counsel Sam Schlessinger Sells 45,236 Shares of Assertio Holdings Inc (GuruFocus.com) -5.44%
Aug-28-23 06:30PM	12 Best High Risk Penny Stocks to Buy Now (Insider Monkey)
Aug-25-23 04:05PM	Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-23-23 08:48AM	Is the Options Market Predicting a Spike in Assertio (ASRT) Stock? (Zacks)
Aug-08-23 04:45PM	Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -7.27%
09:15AM	Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline (Newsfile)
Aug-06-23 08:05AM	Industry Analysts Just Upgraded Their Assertio Holdings, Inc. (NASDAQ:ASRT) Revenue Forecasts By 13% (Simply Wall St.)
07:14AM	10 Oversold Value Stocks To Buy (Insider Monkey)
Aug-03-23 04:29PM	Assertio: Q2 Earnings Snapshot (Associated Press Finance)
04:04PM	Assertio Reports Second Quarter 2023 Financial Results, Closes Spectrum Acquisition (GlobeNewswire)
Jul-31-23 07:27PM	Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction (GlobeNewswire)
Jul-27-23 04:01PM	Assertio Holdings, Inc. Announces Favorable Vote on Proposed Acquisition of Spectrum Pharmaceuticals (GlobeNewswire)
Jul-24-23 08:30AM	Assertio Holdings, Inc. to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023 (GlobeNewswire) +6.17%
Jul-19-23 07:38AM	Assertio Holdings, Inc. (NASDAQ:ASRT) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? (Simply Wall St.)
Jul-07-23 09:16AM	3 Cheap Penny Stocks to Buy Before They Bounce Back (InvestorPlace)
Jun-26-23 07:00AM	Assertio Holdings Joins Russell 3000® Index (GlobeNewswire)
Jun-16-23 06:30AM	Investors in Assertio Holdings (NASDAQ:ASRT) have seen strong returns of 122% over the past year (Simply Wall St.)
May-26-23 12:06PM	Does Assertio Holdings (NASDAQ:ASRT) Deserve A Spot On Your Watchlist? (Simply Wall St.)
May-10-23 06:12AM	Assertio Holdings First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.) +8.17%
01:34AM	Q1 2023 Assertio Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
May-09-23 07:28AM	Assertio: Q1 Earnings Snapshot (AP Finance) +11.50%
07:15AM	Assertio Reports First Quarter 2023 Financial Results, Raises Full Year 2023 Outlook (GlobeNewswire)
06:02AM	Assertio Holdings, Inc.'s (NASDAQ:ASRT) largest shareholders are individual investors with 58% ownership, institutions own 40% (Simply Wall St.)
May-05-23 08:00AM	Assertio Holdings, Inc. Updates First Quarter 2023 Financial Results Call Time to Tuesday, May 9, 2023 at 11:30 am Eastern Time (GlobeNewswire)
May-04-23 10:54AM	Artificial Intelligence Engine Predicts ASRT Stock to Gain 3% by June 1 (InvestorPlace)
06:10AM	7 A-Rated Stocks to Buy for May 2023 (InvestorPlace)
Apr-27-23 09:00AM	Assertio Holdings, Inc. to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023 (GlobeNewswire)
Apr-25-23 01:03PM	Assertio Scoops Up Spectrum Pharma In $248M Stock Deal (Benzinga) -16.09%
06:00AM	Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction (GlobeNewswire)
Apr-24-23 09:00AM	Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
09:00AM	Assertio Provides Educational Grant for New Lennox-Gastaut Syndrome (LGS) Foundation Treatments Kits (GlobeNewswire)
Apr-17-23 06:43AM	The Market Doesn't Like What It Sees From Assertio Holdings, Inc.'s (NASDAQ:ASRT) Earnings Yet (Simply Wall St.)
Apr-10-23 09:00AM	Investors Heavily Search Assertio Holdings, Inc. (ASRT): Here is What You Need to Know (Zacks)
Apr-07-23 04:00PM	Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 (Insider Monkey)
Mar-27-23 09:00AM	Here is What to Know Beyond Why Assertio Holdings, Inc. (ASRT) is a Trending Stock (Zacks)
Mar-14-23 09:00AM	Is Trending Stock Assertio Holdings, Inc. (ASRT) a Buy Now? (Zacks) +12.98%
Mar-10-23 02:37AM	Assertio Holdings, Inc. (NASDAQ:ASRT) Q4 2022 Earnings Call Transcript (Insider Monkey) -13.81%
Mar-09-23 12:19PM	Q4 2022 Assertio Holdings Inc Earnings Call (Thomson Reuters StreetEvents) +11.74%
Mar-08-23 11:43PM	Q4 2022 Aquestive Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
04:01PM	Assertio Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-06-23 09:00AM	Assertio Appoints Dr. Howard Franklin as Senior Vice President, Medical (GlobeNewswire)
06:00AM	7 Thrilling Stocks to Buy for Aggressive Investors (InvestorPlace)
Mar-03-23 09:00AM	Assertio Holdings, Inc. (ASRT) is Attracting Investor Attention: Here is What You Should Know (Zacks) +8.00%
Mar-02-23 08:34AM	Why Earnings Season Could Be Great for Assertio (ASRT) (Zacks)
Mar-01-23 12:41PM	Assertio Holdings, Inc.'s (NASDAQ:ASRT) Intrinsic Value Is Potentially 40% Above Its Share Price (Simply Wall St.) +7.96%
Feb-23-23 07:14AM	Assertio Announces Exchange Offer of $30 Million of its Currently Outstanding 6.50% Convertible Senior Notes Due 2027 (GlobeNewswire) -5.42%
Feb-21-23 07:00AM	Assertio Holdings, Inc. Announces Preliminary Fourth Quarter and Full Year 2022 Results (GlobeNewswire)
Feb-20-23 09:00AM	Assertio Holdings, Inc. (ASRT) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Feb-16-23 08:00AM	Assertio to Participate in the 2023 Winter Wonderland Best Ideas Conference (GlobeNewswire)

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tyree James L	Director	Mar 14 '24	Sale	1.12	10,251	11,463	188,251	Mar 15 08:01 PM
Schlessinger Sam	SVP, General Counsel	Feb 21 '24	Option Exercise	0.00	17,151	0	109,384	Feb 23 05:32 PM
Patel Ajay	SVP and CFO	Feb 21 '24	Option Exercise	0.00	17,151	0	141,760	Feb 23 05:30 PM
Schwichtenberg Paul	SVP, CCO	Feb 21 '24	Option Exercise	0.00	17,151	0	112,430	Feb 23 05:31 PM
Schlessinger Sam	SVP, General Counsel	Feb 11 '24	Option Exercise	0.00	18,939	0	98,785	Feb 13 07:02 PM
Patel Ajay	SVP and CFO	Feb 11 '24	Option Exercise	0.00	47,348	0	140,991	Feb 13 07:00 PM
Schwichtenberg Paul	See Remarks	Feb 11 '24	Option Exercise	0.00	47,348	0	111,661	Feb 13 07:01 PM
Schlessinger Sam	SVP, General Counsel	Oct 01 '23	Option Exercise	0.00	19,404	0	88,442	Oct 03 07:27 PM
Peisert Daniel A.	President & CEO	Sep 12 '23	Sale	2.97	31,121	92,432	324,939	Sep 13 08:15 PM
Peisert Daniel A.	President & CEO	Sep 11 '23	Sale	3.04	127,281	386,972	356,060	Sep 13 08:15 PM
Schwichtenberg Paul	SVP and CFO	Sep 11 '23	Sale	3.07	104,980	322,593	64,313	Sep 13 08:16 PM
Patel Ajay	SVP and CAO	Sep 11 '23	Sale	3.04	64,313	195,794	93,643	Sep 13 08:17 PM
Schlessinger Sam	SVP, General Counsel	Sep 11 '23	Sale	3.04	45,236	137,441	69,038	Sep 13 08:18 PM
MCKEE WILLIAM	Director	Aug 14 '23	Sale	3.14	22,000	69,045	238,780	Aug 15 06:00 PM
Schlessinger Sam	SVP, General Counsel	Aug 05 '23	Option Exercise	0.00	7,135	0	117,434	Aug 08 07:00 PM
Mason Heather L	Director	May 19 '23	Sale	7.30	89,286	652,011	187,650	May 22 08:00 PM
Patel Ajay	SVP and CAO	May 12 '23	Option Exercise	0.00	238,017	0	314,819	May 15 08:58 PM
Schlessinger Sam	SVP, General Counsel	May 12 '23	Option Exercise	0.00	238,017	0	267,162	May 15 08:58 PM
Peisert Daniel A.	President and CEO	May 12 '23	Option Exercise	0.00	552,067	0	797,066	May 15 08:57 PM
Schwichtenberg Paul	SVP and CFO	May 12 '23	Option Exercise	0.00	238,017	0	326,156	May 15 08:58 PM
Tyree James L	Director	May 05 '23	Sale	6.00	43,143	258,767	167,308	May 05 09:10 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

CCCC

C4 Therapeutics Inc

ASRT

Assertio Holdings Inc

Upgrade your FINVIZ experience